Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04329949 · ClinicalTrials.gov registry record · Phase 3
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 3 study, sponsored by Corcept Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 43
- Enrollment target
NCT04329949 is a Phase 3 study that was terminated before completion, run by Corcept Therapeutics. The registered enrollment target is 43 participants.
The verdict
NCT04329949, a Phase 3 study, was terminated before completion, sponsored by Corcept Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.
Interventions
- DRUG Nab-paclitaxel
- DRUG Relacorilant, 100 mg and 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2020-06-30 |
| Est. Completion | 2022-03-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04329949
The ClinicalTrials.gov registry entry for NCT04329949 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nab-paclitaxel is the first listed.
NCT04329949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04329949 about?
NCT04329949 is a clinical study titled "Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma". This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.
What is the current status of trial NCT04329949?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 43 participants. The study started on 2020-06-30. Estimated completion is 2022-03-25.
What interventions are being tested in trial NCT04329949?
The interventions under investigation include: Nab-paclitaxel (DRUG), Relacorilant, 100 mg and 25 mg (DRUG).
Who is sponsoring clinical trial NCT04329949?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.